hiv-1

Documents about hiv-1

• A novel small-molecule inhibitor of HIV-1 entry#7885HAL (France)
• MARCH Central Nervous System Substudy#867278ClinicalTrials.gov
• Study of Bictegravir/Emtricitavine/Tenofovir Alafenamide in HIV-1 Infected naïve Patients Using Test and Treat Stategy Rapid-initiation Model of Care: BIC-NOW Clinical Trial (BIC-NOW)#827225ClinicalTrials.gov
• Presentation 2_HIV-1 molecular transmission networks among MSM in Ningxia, China (2018–2024): insights into local transmission dynamics and drug resistance.pptx#266439Figshare
• Long Acting Cabotegravir Plus Rilpivirine in People Living with HIV-1 Aged ≥ 60 Years for 24 Months.#879532ClinicalTrials.gov
• A Study of Doravirine/Islatravir (DOR/ISL, MK-8591A) for the Treatment of Human Immunodeficiency Virus 1 (HIV-1) Infection in Participants Who Previously Received DOR/ISL (MK-8591A-054)#900726ClinicalTrials.gov
• Doravirine Concentrations and Antiviral Activity in Cerebrospinal Fluid in HIV-1 Infected Individuals#910581ClinicalTrials.gov
• Effectiveness of AZT and Nevirapine in Preventing HIV Transmission From Ugandan Mothers to Their Newborns#863517ClinicalTrials.gov
• Impact of Cotrimoxazole Use in Immunocompetent HIV Patients on Carriage of Antimicrobial Resistant Bacteria#123490ClinicalTrials.gov
• "Metal-based compounds in antiviral and Antiparasitic research: Mechanistic insights from HIV NCp7 and leishmaniasis case studies".#190383PubMed
• Supplementary File 1. HIV and tuberculosis in Latvia: patient characteristics and evaluation of tuberculosis screening coverage.#243674Figshare
• A Study of Safety and Drug Levels of ePGT121v1-LS, PGDM1400LS, and VRC07-523LS in Adult Participants Without HIV-1#314386ClinicalTrials.gov
• Model-free based control of a HIV/AIDS prevention model#315035HAL (France)
• Assess and Adapt to the Impact of COVID-19 on CVD Self-Management and Prevention Care in Adults Living With HIV#424277ClinicalTrials.gov
• A Clinical Trial to Look at the Safety and Immune Responses of the RNA-based Vaccine BNT168 in Adults Living With or Without HIV#463755ClinicalTrials.gov
• Three Chemo Regimens as an Adjunct to ART for Treatment of Advanced AIDS-KS#858878ClinicalTrials.gov
• Switching Nevirapine Immediate Release( IR) Based Regimen to Nevirapine Extended Release (XR) Based Regimen in Human Immunodeficiency Virus One (HIV-1) Infected Patients#903749ClinicalTrials.gov
• 2DR Versus 3DR in a Prospective Randomized Controlled Switch Trial#905394ClinicalTrials.gov
• Safety and Efficacy of Triptolide Wilfordii in New Onset HIV-1 Infection#911599ClinicalTrials.gov
• Safety/Immunogenicity of Immunizations of ALVAC-DC-SC vs ALVAC-SC#807755ClinicalTrials.gov
• A Proof of Concept Study to Evaluate the Antiviral Activity, Safety, and Pharmacokinetics of the CCR5 Antagonist TBR 652 in HIV 1-Infected, Antiretroviral Treatment-Experienced, CCR5 Antagonist-Naïve Patients#837898ClinicalTrials.gov
• A Study to Compare Anti-HIV Drugs Given Twice a Day or Once a Day, With or Without Direct Observation#885469ClinicalTrials.gov
• A Phase I Comparative Blinded Trial of Several HIV-1 Derived Immunogens in Infected Individuals With >= 500 CD4 Cells/mm3#123530ClinicalTrials.gov
• Evaluation de l'accès au diagnostic VIH chez les enfants exposés en Afrique Subsaharienne#124518HAL (France)
• A Multicenter, Randomized, Placebo-Controlled, Double-Blind Trial to Evaluate the Safety and Immunogenicity of an HIV-1 Pseudovirion Vaccine#148588ClinicalTrials.gov
• Safety, Tolerability and Immunogenicity Induced by the THV01 Treatment in Patients Infected With HIV-1 Clade B and Treated With Highly Active Antiretroviral Therapy (HAART).#195396ClinicalTrials.gov
• Outcomes for persons with triple-class resistant HIV and a history of virologic failure#643179HAL (France)
• Pharmacokinetics of Single-dose Dolutegravir in HIV-seronegative Subjects With Severe Hepatic Impairment Compared to Matched Controls.#825239ClinicalTrials.gov
• A Study of Switching to RPV Plus Other ARVs in HIV-1-infected Children (Aged 2 to <12 Years) Who Are Virologically Suppressed#905085ClinicalTrials.gov
• Sofosbuvir-Containing Regimens Without Interferon For Treatment of Acute Hepatitis C Virus (HCV) Infection#906420ClinicalTrials.gov
• Open-label, Phase I/IIa Study of VAC-3S in HIV-1 Patients Who Showed an Immune Response to VAC-3S During IVVAC-3S/P1#918410ClinicalTrials.gov
• Vietnam Cryptococcal Retention in Care Study - Version 2.1#969192ClinicalTrials.gov
• Primary and Secondary Drug Resistance Mutations (DRMs) in HIV As a Risk Factor of Failure of ART, Including Two Drugs Based Regimens.#858751ClinicalTrials.gov
• Efficacy and Safety of Low-Dose Colchicine on Surrogate Markers of Cardiovascular Events in People Living With HIV Receiving Antiretroviral Therapy#873235ClinicalTrials.gov
• BRCA1-RAD51 homologous DNA repair pathway promotes HIV-1 reverse transcription#442561HAL (France)
• Fuzeon Viral Decay Pilot Study#859522ClinicalTrials.gov
• Interplay Between Oral Microbiota and Mouth Health in People Living With HIV Under Antiretroviral Therapy With or Without Periodontitis#14408HAL (France)
• The strictly conserved GGG-tracts in the 5' and 3' long terminal repeat of HIV-1 are critical to control multiple steps of HIV-1 replication to prevent acquisition of unwanted mutations in the region#223916bioRxiv / medRxiv
• Hiding in Plain Sight: HIV-1 Membraneless Organelles as Nuclear Hubs—Host Hijacking, Replication, Immune Evasion, and Drug-Access Implications#442564HAL (France)
• Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of E/C/F/TAF Fixed Dose Combination (FDC) in HIV-1 Infected Adults on Chronic Hemodialysis#849001ClinicalTrials.gov
• Evaluation of the Changes in HIV-1 Burden in Peripheral Blood and Lymphoid Tissue Following Zidovudine ( AZT ) Treatment in HIV-1-Infected Patients With CD4+ Cells Between 100 and 500 Cells/mm3.#1046084ClinicalTrials.gov
• A Study to Assess the Efficacy of Raltegravir (Isentress®), Administered in Combination With Other Antiretroviral Drugs as Treatment for Adults and Older Adults Infected With the Human Immunodeficiency Virus 1 (HIV-1)(MK-0518-145) (Wirksamkeit Von Isentress® Unter Praxisbedingungen)#383495ClinicalTrials.gov
• A Phase I, Multicenter, Randomized Trial to Evaluate the Safety and Immunogenicity of Vaccinia-Derived MN HIV-1 Recombinant Envelope Glycoprotein (rgp160) of Human Immunodeficiency Virus at Two Different Vaccination Schedules#143654ClinicalTrials.gov
• A Multicenter, Randomized, Placebo-Controlled, Double-Blinded, Phase I Trial to Evaluate the Safety and Immunogenicity of Live Recombinant Canarypox ALVAC-HIV vCP205 Combined With GM-CSF in Healthy, HIV-1 Uninfected Volunteers#148557ClinicalTrials.gov
• TMC278-TiDP6-C215: A Clinical Trial in Treatment Naive HIV-subjects Patients Comparing TMC278 to Efavirenz in Combination With 2 Nucleoside/Nucleotide Reverse Transcriptase Inhibitors#824809ClinicalTrials.gov
• KSHV Acquired During Chemsex With Resultant Multicentric Castleman's Disease in a Patient Successfully Treated for HIV#378106HAL (France)
• Intermittent Therapy in HIV-1 Infected Patients With Successful Viral Suppression Under Highly Active Antiretroviral Therapy (HAART)#861797ClinicalTrials.gov
• GSK3640254 First Time in Human (FTIH) Study in Healthy Volunteers#906304ClinicalTrials.gov
• Long-Acting Cabotegravir Plus VRC-HIVMAB075-00-AB (VRC07-523LS) for Viral Suppression in Adults Living With HIV-1#906818ClinicalTrials.gov
• Vulnerabilidade e resiliência entre adolescentes e jovens vivendo com HIV/SIDA na cidade de Maputo, Moçambique : Kuhanya - o contágio da vida#1040782Repositório Institucional da UnB